Search Results

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global Investment Conference.

HiberCell, a clinical-stage biotechnology company dedicated to addressing mechanisms of treatment resistance, cancer relapse, and metastasis, today announced the successful completion of its Phase 1 study of the novel PERK inhibitor, HC-5404, in solid tumors along with two pre-clinical publications in one of the leading journals of AACR, Clinical Cancer Research (CCR).

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”) today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022.

Today hc1, the leader in clinical insight, analytics and solutions for precision health, introduced hc1 Rapid Response Queue™, a new add-on solution for hc1 Operations Management™.